Terry J. Fry

University of Colorado Anschutz Medical Campus — United States

Medicine · Health Sciences

60h-index22.6kcitations354works2.72yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

CAR-T cell therapy research(212), Immune Cell Function and Interaction(94), Immunotherapy and Immune Responses(68), Hematopoietic Stem Cell Transplantation(56), Viral Infectious Diseases and Gene Expression in Insects(53)

Publications353 total

Abstract B014: Investigating universal mechanisms of leukemic cell resistance to CAR-T cell therapy
Cancer Immunology Research·2026
Abstract C005: Understanding the Role of Tonic TCR Signaling to Optimize CAR-T Efficacy
Cancer Immunology Research·2026
Ten-year experience of CD22 CAR T cells for children and young adults with B-cell acute lymphoblastic leukemia
Blood Advances·2025Open Access
Rational redesign of antigen binding domain improves in vivo efficacy of the CD22-CAR
Molecular Therapy·2025
High Precision Peptide-MHC Class I CARs Enhance <i>In Vivo</i> Killing of Targeted CD8 T Cells to Prevent Type 1 Diabetes in Novel RIP-mOVA Model
2025Open Access
From bench to IND: Validation of TSLPR CAR T-cells reveal discrepancies in detection modalities and inform dose selection for a Phase 1 clinical trial in relapsed/refractory CRLF2-rearranged B-ALL patients.
Blood·2025
UCD19 CAR-T cell therapy for adults with B-cell acute lymphoblastic leukemia in first complete remission with MRD positivity: Preliminary Results of A phase I/ib clincal trial
Blood·2025Open Access
CD19/22 CAR T-cells in children and young adults with B-ALL: Final Phase 1 trial results
Blood·2025
Early use of talicabtagene autoleucel in r/r B-acute lymphoblastic leukemia is cost-effective: Improved efficacy, reduced toxicity and healthcare resource utilization support affordable access
Blood·2025Open Access
Tali-cel is a safe and effective therapy in patients with Relapsed/Refractory B-cell non-Hodgkin lymphoma that allows equitable access- a real-world experience from India.
Blood·2025Open Access
Increased NFAT activity with dual CAR stimulation in CD19xCD22 CAR T-cells is associated with decreased exhaustion and improved survival
Journal for ImmunoTherapy of Cancer·2025Open Access
Outcomes following CD22 CAR T-cells in B-ALL: a tale of two manufacturing strategies
Cytotherapy·2025Open Access
Hypoxia-regulatable CAR T cells
Molecular Therapy·2025Open Access
Unsupervised Machine Learning‐Based Process Analytical Tools for Near Real‐Time Cell Morphology Analysis During CAR‐T Cell Manufacturing
Biotechnology and Bioengineering·2025· 3 cited
Abstract 4801: T-bet overexpression promotes CAR T cell potency and responsiveness to low antigen density leukemia
Cancer Research·2025
The Paradox of Acute Myeloid Leukemia Responsiveness to Adoptive T-cell Therapy
Blood Cancer Discovery·2025Open Access
Characterization of a multiplex digital PCR assay to quantify total T cells relative to chimeric antigen receptor-positive T cells
Molecular Therapy Oncology·2025· 1 citedOpen Access
T-bet overexpression enhances CAR T cell effector functions and antigen sensitivity
Journal for ImmunoTherapy of Cancer·2025· 4 citedOpen Access
Rational redesign of antigen binding domain improves <i>in vivo</i> efficacy of CD22-CAR T cells
2025Open Access
Talicabtagene autoleucel for relapsed or refractory B-cell malignancies: results from an open-label, multicentre, phase 1/2 study
The Lancet Haematology·2025· 8 cited
page 1 of 18Next →

Frequent Co-authors

Crystal L. Mackall(19), Nirali N. Shah(15), Crystal L. Mackall(13), Haiying Qin(12), Maryalice Stetler‐Stevenson(11), Constance M. Yuan(11), Ronald E. Gress(9), Bonnie Yates(8), David F. Stroncek(8), Haneen Shalabi(7), James N. Kochenderfer(6), Cindy Delbrook(6), Seth M. Steinberg(6), Jack F. Shern(6), Daniel W. Lee(6), Rimas J. Orentas(5), Sang M. Nguyen(5), Elad Jacoby(5), Steven L. Highfill(5), Marianna Sabatino(4)